Osteoporosis is a disease of bones that leads to an increased risk of fracture. In osteoporosis the bone mineral density is reduced, bone microarchitecture deteriorates, and the amount and variety of proteins in bone is altered. Osteoporosis risks can be reduced with lifestyle changes and sometimes medication; in people with osteoporosis, treatment may involve both.
Osteoporosis Stories
  • IOF campaign puts spotlight on vastly under-diagnosed and under-treated spinal fractures

    At a press conference held in Brussels today, the International Osteoporosis Foundation (IOF), the Belgian Bone Club and the European Parliament Osteoporosis Interest Group called on health care professionals and health policy officials in Europe to take action to prevent spinal fractures.
  • Warner Chilcott announces FDA approval of next generation Actonel

    Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its next generation ACTONEL® (risedronate sodium) product for the treatment of postmenopausal osteoporosis in the United States.
  • Controlling bone formation to prevent osteoporosis

    Aging disrupts the balance between bone formation and bone destruction, resulting in osteoporosis, which is characterized by reduced bone mass and increased risk of fracture.
  • New computer-tomography method visualizes nano-structure of bones

    A novel nano-tomography method developed by a team of researchers from the Technische Universitaet Muenchen, the Paul Scherrer Institute and the ETH-Zurich opens the door to computed tomography examinations of minute structures at nanometer resolutions. Three-dimensional detailed imaging of fragile bone structures becomes possible. Their first nano-CT images will be published in Nature on Sept. 23, 2010. This new technique will facilitate advances in both life sciences and materials sciences.
  • Genetic factor in osteoporosis discovered

    Spanish researchers have confirmed there is a genetic risk factor for osteoporosis and bone fractures. Although more studies are still needed, these findings will make it possible to take preventive measures.
  • New task force report on bisphosphonate use and atypical femur fractures in osteoporosis patients

    A widely prescribed class of drugs is highly effective in reducing common bone fractures in people with osteoporosis, but an expert panel announced today that these same drugs – when used long term – may be related to unusual but serious fractures of the thigh bone. In the most comprehensive scientific report to date on the topic, the task force reviewed 310 cases of "atypical femur fractures," and found that 94 percent (291) of patients had taken the drugs, most for more than five years. The task force members emphasized that atypical femur fractures represent less than one percent of hip and thigh fractures overall and therefore are very uncommon.
  • Osteoporosis fractures significantly reduce quality of life

    University of Sydney researchers studying the impact of fractures from osteoporosis have found female sufferers experienced a significant reduction in their quality of life similar to or worse than that of patients with diabetes, arthritis, lung disease and other chronic illnesses.
  • Seven ways to deal with osteopenia

    Osteopenia is early sign of bone loss that can turn into osteoporosis. It is a precursor to the debilitating disease that results in disfigurement and serious bone problems.
  • Drugs used to treat osteoporosis not linked with higher risk of esophageal cancer

    Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue ofJAMA.
  • American oriental bioengineering to launch new boke brand osteoporosis drug

    American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced the commercial launch of Boke brand Yi Shen Jian Gu Gel ("YSJG" Gel) after successful test marketing in the second quarter of 2010.
  • Protein identified that can result in fragile bones

    Too little of a protein called neogenin results in a smaller skeleton during development and sets the stage for a more fragile bone framework lifelong, Medical College of Georgia researchers report.
  • Eight things you need to know about osteoarthritis

    Osteoarthritis is a disease that affects the joints and the cartilage, the soft tissue that covers the ends of bones in a joint. Healthy cartilage is slippery and allows bones to glide over each other. It also helps absorb shock of movement.